Intensity Therapeutics reports complete pathological response in 5 of 7 breast cancer trial patients

INTS•2026-10-23

Intensity Therapeutics reported a complete pathological response in 5 of 7 patients receiving INT230-6 plus standard care in a breast cancer trial. All seven qualified for breast-conserving surgery, and dose-limiting skin reactions prompted a protocol change.

Intensity Therapeutics reports complete pathological response in 5 of 7 breast cancer trial patients

1. Initial trial results

Related News

B. Riley cuts Alpha and Omega Semiconductor target price to $25 from $34

Inspired Entertainment, Inc.: B. Riley cuts target price to $8.75 from $13

Southern Copper Corporation: Wells Fargo raises target price to $193 from $190

Preferred Bank's Q3 net interest income falls due to nonaccrual loans

Waters partners with Labcorp to expand access to cervical cancer screening